Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more
Gan & Lee Pharmaceuticals Co Ltd (603087) - Net Assets
Latest net assets as of September 2025: CN¥11.28 Billion CNY
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) has net assets worth CN¥11.28 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.14 Billion) and total liabilities (CN¥860.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥11.28 Billion |
| % of Total Assets | 92.91% |
| Annual Growth Rate | 27.97% |
| 5-Year Change | 23.67% |
| 10-Year Change | 644.03% |
| Growth Volatility | 20.93 |
Gan & Lee Pharmaceuticals Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gan & Lee Pharmaceuticals Co Ltd (2013–2024)
The table below shows the annual net assets of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥11.05 Billion | +2.90% |
| 2023-12-31 | CN¥10.74 Billion | +12.07% |
| 2022-12-31 | CN¥9.59 Billion | -5.72% |
| 2021-12-31 | CN¥10.17 Billion | +13.75% |
| 2020-12-31 | CN¥8.94 Billion | +63.38% |
| 2019-12-31 | CN¥5.47 Billion | +28.10% |
| 2018-12-31 | CN¥4.27 Billion | +28.04% |
| 2017-12-31 | CN¥3.34 Billion | +47.85% |
| 2016-12-31 | CN¥2.26 Billion | +51.83% |
| 2015-12-31 | CN¥1.49 Billion | +43.10% |
| 2014-12-31 | CN¥1.04 Billion | +41.60% |
| 2013-12-31 | CN¥733.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gan & Lee Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2448.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.76 Billion | 61.14% |
| Common Stock | CN¥601.07 Million | 5.44% |
| Other Comprehensive Income | CN¥4.04 Million | 0.04% |
| Other Components | CN¥3.69 Billion | 33.39% |
| Total Equity | CN¥11.05 Billion | 100.00% |
Gan & Lee Pharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Gan & Lee Pharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FDJ United
LSE:0A8B
|
$2.68 Billion |
|
Rubis SCA
PA:RUI
|
$2.68 Billion |
|
Vodacom Group Ltd PK
PINK:VDMCY
|
$2.68 Billion |
|
IPCA Laboratories Limited
NSE:IPCALAB
|
$2.68 Billion |
|
Cembra Money Bank AG
PINK:CMBNF
|
$2.67 Billion |
|
Galp Energa
PINK:GLPEY
|
$2.67 Billion |
|
Konecranes ABP
LSE:0MET
|
$2.67 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
$2.67 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gan & Lee Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,742,506,022 to 11,054,470,662, a change of 311,964,640 (2.9%).
- Net income of 614,663,846 contributed positively to equity growth.
- Dividend payments of 420,547,253 reduced retained earnings.
- Other comprehensive income increased equity by 219,526.
- Other factors increased equity by 117,628,521.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥614.66 Million | +5.56% |
| Dividends Paid | CN¥420.55 Million | -3.8% |
| Other Comprehensive Income | CN¥219.53K | +0.0% |
| Other Changes | CN¥117.63 Million | +1.06% |
| Total Change | CN¥- | 2.90% |
Book Value vs Market Value Analysis
This analysis compares Gan & Lee Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 39.82x to 3.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.56 | CN¥62.13 | x |
| 2014-12-31 | CN¥2.02 | CN¥62.13 | x |
| 2015-12-31 | CN¥2.92 | CN¥62.13 | x |
| 2016-12-31 | CN¥4.44 | CN¥62.13 | x |
| 2017-12-31 | CN¥6.60 | CN¥62.13 | x |
| 2018-12-31 | CN¥8.46 | CN¥62.13 | x |
| 2019-12-31 | CN¥9.74 | CN¥62.13 | x |
| 2020-12-31 | CN¥15.92 | CN¥62.13 | x |
| 2021-12-31 | CN¥18.11 | CN¥62.13 | x |
| 2022-12-31 | CN¥17.07 | CN¥62.13 | x |
| 2023-12-31 | CN¥18.95 | CN¥62.13 | x |
| 2024-12-31 | CN¥18.70 | CN¥62.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gan & Lee Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.56%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.18%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.09x
- Recent ROE (5.56%) is below the historical average (19.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 27.92% | 29.56% | 0.83x | 1.14x | CN¥131.41 Million |
| 2014 | 29.39% | 32.94% | 0.77x | 1.16x | CN¥201.38 Million |
| 2015 | 30.11% | 36.68% | 0.67x | 1.22x | CN¥298.83 Million |
| 2016 | 34.11% | 43.45% | 0.68x | 1.15x | CN¥544.03 Million |
| 2017 | 32.38% | 45.56% | 0.63x | 1.12x | CN¥746.41 Million |
| 2018 | 21.87% | 39.12% | 0.51x | 1.10x | CN¥506.88 Million |
| 2019 | 21.34% | 40.32% | 0.48x | 1.10x | CN¥620.18 Million |
| 2020 | 13.77% | 36.61% | 0.35x | 1.06x | CN¥336.86 Million |
| 2021 | 14.29% | 40.22% | 0.33x | 1.07x | CN¥436.02 Million |
| 2022 | -4.59% | -25.67% | 0.16x | 1.11x | CN¥-1.40 Billion |
| 2023 | 3.17% | 13.04% | 0.22x | 1.09x | CN¥-734.18 Million |
| 2024 | 5.56% | 20.18% | 0.25x | 1.09x | CN¥-490.78 Million |
Industry Comparison
This section compares Gan & Lee Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,246,530,775
- Average return on equity (ROE) among peers: 12.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gan & Lee Pharmaceuticals Co Ltd (603087) | CN¥11.28 Billion | 27.92% | 0.08x | $2.68 Billion |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $234.74 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $784.88 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.62 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |